# ICARIA-MM (NCT02990338)

> Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02990338
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Sanofi
- Conditions: Plasma Cell Myeloma
- Interventions: Isatuximab; Pomalidomide; Dexamethasone
- Enrollment: 307
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11
- Podcasts: 3
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=icaria-mm-nct02990338

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02990338", "email": "<work email>"}; the inbox owner confirms by the emailed link.